-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Gf0OslmcxFxFj/4a2OW+uJeK1jhdGTEjONC9Cuy/jmGj/TcLgQY2+wht2yR2LpqU 7F5DjCievYoKiYN/jBn5eA== 0000051396-98-000019.txt : 19980304 0000051396-98-000019.hdr.sgml : 19980304 ACCESSION NUMBER: 0000051396-98-000019 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19980303 SROS: CSE SROS: NYSE SROS: PCX SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SYNBIOTICS CORP CENTRAL INDEX KEY: 0000719483 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 953737816 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: SEC FILE NUMBER: 005-37439 FILM NUMBER: 98555478 BUSINESS ADDRESS: STREET 1: 11011 VIA FRONTERA CITY: SAN DIEGO STATE: CA ZIP: 92127 BUSINESS PHONE: 6194513771 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MALLINCKRODT INC /MO CENTRAL INDEX KEY: 0000051396 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 361263901 STATE OF INCORPORATION: NY FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: 675 MCDONNELL BLVD STREET 2: PO BOX 5840 CITY: ST LOUIS STATE: MO ZIP: 63134 BUSINESS PHONE: 3146542000 MAIL ADDRESS: STREET 1: 7733 FORSYTH BLVD CITY: ST LOUIS STATE: MO ZIP: 63105-1820 FORMER COMPANY: FORMER CONFORMED NAME: MALLINCKRODT INC /MO DATE OF NAME CHANGE: 19970625 FORMER COMPANY: FORMER CONFORMED NAME: MALLINCKRODT GROUP INC DATE OF NAME CHANGE: 19940322 FORMER COMPANY: FORMER CONFORMED NAME: IMCERA GROUP INC DATE OF NAME CHANGE: 19920703 SC 13D 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) Synbiotics Corporation ______________________________________________________________________________ (Name of Issuer) Common Stock, no par value ______________________________________________________________________________ (Title of Class of Securities) 87156610 ______________________________________________________________________________ (CUSIP Number) Roger A. Keller, 675 McDonnell Blvd., P. O. Box 5840 St. Louis, MO 63134 (314) 654-5242 ______________________________________________________________________________ (Name, Address and Telephone No. Of Person Authorized to Receive Notices and Communications) November 20, 1997 ______________________________________________________________________________ (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b) (3) or (4), check the following box. / / Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). ______________________________________________________________________________ 1. NAME OF REPORTING PERSON S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Mallinckrodt Inc. 36-1263901 ______________________________________________________________________________ 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) / / N/A (b) / / ______________________________________________________________________________ 3. SEC USE ONLY ______________________________________________________________________________ 4. SOURCE OF FUNDS 00 ______________________________________________________________________________ 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) N/A / / ______________________________________________________________________________ 6. CITIZENSHIP OR PLACE OF ORGANIZATION New York ______________________________________________________________________________ 7. SOLE VOTING POWER NUMBER OF 392,639 SHARES _______________________________________________________________ BENEFICIALLY 8. SHARED VOTING POWER OWNED BY N/A EACH _______________________________________________________________ REPORTING 9. SOLE DISPOSITIVE POWER PERSON 392,639 WITH _______________________________________________________________ 10. SHARED DISPOSITIVE POWER N/A ______________________________________________________________________________ 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 392,639 ______________________________________________________________________________ 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES / / N/A ______________________________________________________________________________ 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.8% ______________________________________________________________________________ 14. TYPE OF REPORTING PERSON CO ______________________________________________________________________________ Item 1. Security and Issuer. This statement relates to the Common Stock, no par value (the "Common Stock"), of Synbiotics Corporation, a California corporation (the "Issuer"), whose executive offices are located at 11011 Via Frontera Drive, San Diego, CA 92127. Item 2. Identity and Background. Mallinckrodt Inc. is a New York corporation ("Mallinckrodt") whose principal business is the production and sale of specialty pharmaceutical and highly selected specialty industrial chemicals; and the production and sale of human health products in the fields of cardiology, radiology, respiratory care, anesthesiology, nuclear medicine and critical care. Mallinckrodt's principal office is located at 675 McDonnell Boulevard, St. Louis, Missouri 63134. During the last five years, neither Mallinckrodt nor any of its executive officers, directors or controlling persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). During the last five years, neither Mallinckrodt nor any of its executive officers, directors or controlling persons has been and is not now (a) subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to,federal or state securities laws, or (b) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction finding any violation with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration. No change from information in Mallinckrodt's prior filings on Schedule 13D with respect to the Common Stock. Item 4. Purpose of Transaction. No change from information in Mallinckrodt's prior filings on Schedule 13D with respect to the Common Stock. Item 5. Interest in Securities of the Issuer. (a) As of the date of the event which required the filing of this statement (November 20, 1997), Mallinckrodt beneficially owned 433,639 shares of Common Stock of the Issuer, representing approximately 5.3% of the issued and outstanding shares of the Common Stock. As of the date of this filing (February 16, 1998), Mallinckrodt beneficially owned 392,639 shares of Common Stock of the Issuer, representing approximately 4.8% of the issued and outstanding shares of the Common Stock. (b) Mallinckrodt had voting and dispositive power with respect to all shares of the Common Stock referenced in response to Item 5(a). (c) Mallinckrodt engaged in the following sales of the Common Stock in the 60 day period ending on February 16, 1998: Date Shares Price Where January 2, 1998 1,000 3.063 Open market January 5, 1998 1,000 3.000 " " January 6, 1998 1,000 3.000 " " January 7, 1998 1,000 3.063 " " January 8, 1998 1,000 3.125 " " January 9, 1998 1,000 3.188 " " January 12, 1998 1,000 3.125 " " January 13, 1998 1,000 3.125 " " January 14, 1998 1,000 3.125 " " January 15, 1998 1,000 3.125 " " January 16, 1998 1,000 3.125 " " January 20, 1998 1,000 3.188 " " January 21, 1998 1,000 3.188 " " January 22, 1998 1,000 3.188 " " January 23, 1998 1,000 3.188 " " January 26, 1998 1,000 3.188 " " January 27, 1998 1,000 3.188 " " January 28, 1998 1,000 3.188 " " January 29, 1998 1,000 3.188 " " January 30, 1998 1,000 3.188 " " February 2, 1998 1,000 3.188 " " February 3, 1998 1,000 3.188 " " February 4, 1998 1,000 3.188 " " February 6, 1998 1,000 3.188 " " February 9, 1998 1,000 3.188 " " February 10, 1998 1,000 3.188 " " February 11, 1998 1,000 3.156 " " February 13, 1998 1,000 3.156 " "
(d) Not applicable. (e) Mallinckrodt ceased to be the beneficial owner of more than five percent of the Common Stock on or about January 20, 1998. Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. No change from information contained in Mallinckrodt's prior filings on Schedule 13D with respect to the Common Stock. Item 7. Material to be Filed as Exhibits No change from exhibits filed with Mallinckrodt's prior filings on Schedule 13D with respect to the Common Stock. Signature After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: February 16, 1998 MALLINCKRODT INC., a New York corporation /s/ Roger A. Keller _______________________________________ Name: Roger A. Keller Title: Vice President, Secretary & General Counsel -----END PRIVACY-ENHANCED MESSAGE-----